JonesTrading Keeps Their Buy Rating on aTyr Pharma (LIFE)
TipRanks · 03/13 11:55
Roku Has 26% Of Cash With SVB Financial, Deposit Recovery Uncertain — 27 Other Companies With Ties To Collapsed Bank
Benzinga · 03/11 19:27
BRIEF-Atyr Pharma -As Of March 10, 2023, Co Holds Less Than 2% Of Its Current Cash, Cash Equivalents, Restricted Cash & Available For Sale Investments With Svb
Reuters · 03/10 22:52
Where aTyr Pharma Stands With Analysts
Benzinga · 03/10 15:01
RBC Capital Reiterates Outperform on aTyr Pharma, Maintains $19 Price Target
Benzinga · 03/10 14:34
Analysts Offer Insights on Healthcare Companies: aTyr Pharma (LIFE), COMPASS Pathways (CMPS) and Olema Pharmaceuticals (OLMA)
TipRanks · 03/10 11:20
Atyr Pharma (LIFE) Reports Q4 Loss, Tops Revenue Estimates
NASDAQ · 03/09 22:15
ATyr Pharma Cash, Restricted Cash, Cash Equivalents And Investments As Of December 31, 2022, Were $69.3M
Benzinga · 03/09 21:02
aTyr Pharma GAAP EPS of -$0.26 beats by $0.22, revenue of $10.4M beats by $10.15M
Seeking Alpha · 03/09 21:02
BRIEF-aTyr Pharma Inc Believes Cash Runway Will Extend Into 2026
Reuters · 03/09 21:01
-- Earnings Flash (LIFE) ATYR PHARMA Reports Q4 Revenue $10.4M
-- Earnings Flash (LIFE) ATYR PHARMA Reports Q4 Revenue $10.4M
MT Newswires · 03/09 16:09
Earnings Scheduled For March 9, 2023
Benzinga · 03/09 13:00
Notable earnings after Thursday's close
Seeking Alpha · 03/08 22:35
aTyr Pharma's Earnings: A Preview
Benzinga · 03/08 17:02
Roth MKM Reinstates Buy on aTyr Pharma, Announces $9 Price Target
Benzinga · 03/06 15:13
RBC Cuts Price Target on aTyr Pharma to $19 From $20, Maintains Outperform, Speculative Risk
RBC Cuts Price Target on aTyr Pharma to $19 From $20, Maintains Outperform, Speculative Risk
MT Newswires · 03/02 08:20
H.C. Wainwright Sticks to Their Buy Rating for aTyr Pharma (LIFE)
TipRanks · 03/01 15:45
Atyr Pharma's Efzofitimod Has Received FDA For Systemic Sclerosis (SSc) And Fast Track Designation For SSc-Associated Interstitial Lung Disease (SSc-ILD); Proof-of-concept Study In SSc-ILD Expected To Begin In 2023
Benzinga · 03/01 13:22
Atyr Pharma (LIFE) Upgraded to Buy: Here's What You Should Know
NASDAQ · 02/17 17:00
BRIEF-Atyr Pharma Announces Pricing Of Public Offering Of Common Stock
Reuters · 02/09 14:01
Webull provides a variety of real-time LIFE stock news. You can receive the latest news about Atyr Pharma Inc through multiple platforms. This information may help you make smarter investment decisions.
About LIFE
aTyr Pharma, Inc. is a biotherapeutics company engaged in the discovery and development of medicines based on novel biological pathways. Its therapeutic candidate pipeline includes efzofitimod (ATYR1923), ATYR2810, NRP2 mAbs, AARS-1 and DARS-1. The ATYR1923, is a fusion protein comprised of the immunomodulatory domain of histidyl-tRNA synthetase fused to the fragment crystallizable (Fc) region of a human antibody and serves as a selective modulator of NRP2 that downregulates innate and adaptive immune response in inflammatory disease states. The Company is also developing efzofitimod as a potential disease-modifying therapy for patients with fibrotic lung diseases with high unmet medical need. ATYR2810 is a fully humanized monoclonal antibody that specifically and functionally blocks the interaction between NRP2 and one of its primary ligands VEGF. ATYR2810 is in preclinical development for the potential treatment of certain aggressive cancers where NRP2 is implicated.